Release Date: January 7, 2026
Expiration Date: January 7, 2027
Activity Overview
Asparaginase is the cornerstone of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) treatment, which generally includes combination treatment with chemotherapy and radiotherapy. Although general principles of ALL/LBL treatment have emerged and are followed in most cancer treatment centers, identifying immunogenic reactions, optimizing therapeutic drug monitoring, and switching between asparaginase preparations are among the many challenges practitioners face when managing adolescent, young adult, and adult patients with ALL/LBL.
This symposium features our Cases & Conversations™ format, in which 3 clinical experts use case-based discussions to highlight clinically relevant aspects of using asparaginase formulations for ALL/LBL. This engaging format is designed to help clinicians identify best clinical practices regarding selecting asparaginase therapy, monitoring for adverse events, and using multidisciplinary strategies to improve outcomes for their patients with ALL/LBL.
This educational activity is an archive of the live presentation held on December 5, 2025.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational activity is directed toward physicians, nurses, nurse practitioners, physician assistants, pharmacists, and other health care providers involved in the diagnosis and treatment of ALL/LBL.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Utilize current best practices to monitor and manage adverse events (AEs) and toxicities associated with various asparaginase formulations for ALL/LBL
- Examine current data and ongoing clinical trials on approved and emerging asparaginase formulations for ALL/LBL
- Identify patients with ALL/LBL who should be switched to an alternative asparaginase formulation upon the development of hypersensitivity or silent inactivation
- Apply multidisciplinary strategies to address asparaginase-associated AEs and toxicities, including distinguishing between hypersensitivity reactions and infusion reactions
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here